Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol phase 3 trial in active progressive psoriatic arthritis
NL-OMON36257Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Sep 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in psoriatic arthritis (PsA) and psoriasis (3 arms), sponsored by UCB. Started Sep 2010; status: active, not recruiting.
02
Drugs
certolizumab pegol
03
Conditions
psoriatic arthritis (PsA)psoriasis
Beyond the preview
Go deeper on NL-OMON36257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36257.